78 related articles for article (PubMed ID: 11180447)
1. Pseudo-likelihood estimates of the cumulative risk of an autosomal dominant disease from a kin-cohort study.
Moore DF; Chatterjee N; Pee D; Gail MH
Genet Epidemiol; 2001 Feb; 20(2):210-27. PubMed ID: 11180447
[TBL] [Abstract][Full Text] [Related]
2. Association and aggregation analysis using kin-cohort designs with applications to genotype and family history data from the Washington Ashkenazi Study.
Chatterjee N; Shih J; Hartge P; Brody L; Tucker M; Wacholder S
Genet Epidemiol; 2001 Sep; 21(2):123-38. PubMed ID: 11507721
[TBL] [Abstract][Full Text] [Related]
3. Designing studies to estimate the penetrance of an identified autosomal dominant mutation: cohort, case-control, and genotyped-proband designs.
Gail MH; Pee D; Benichou J; Carroll R
Genet Epidemiol; 1999; 16(1):15-39. PubMed ID: 9915565
[TBL] [Abstract][Full Text] [Related]
4. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
[TBL] [Abstract][Full Text] [Related]
5. The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Offit K; Foulkes W; Robson ME; Wacholder S; Eng CM; Karp SE; Begg CB
Cancer Epidemiol Biomarkers Prev; 2001 May; 10(5):467-73. PubMed ID: 11352856
[TBL] [Abstract][Full Text] [Related]
6. Population-based study of changing breast cancer risk in Icelandic BRCA2 mutation carriers, 1920-2000.
Tryggvadottir L; Sigvaldason H; Olafsdottir GH; Jonasson JG; Jonsson T; Tulinius H; Eyfjörd JE
J Natl Cancer Inst; 2006 Jan; 98(2):116-22. PubMed ID: 16418514
[TBL] [Abstract][Full Text] [Related]
7. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
[TBL] [Abstract][Full Text] [Related]
8. Penetrances of breast and ovarian cancer in a large series of families tested for BRCA1/2 mutations.
Marroni F; Aretini P; D'Andrea E; Caligo MA; Cortesi L; Viel A; Ricevuto E; Montagna M; Cipollini G; Federico M; Santarosa M; Marchetti P; Bailey-Wilson JE; Bevilacqua G; Parmigiani G; Presciuttini S
Eur J Hum Genet; 2004 Nov; 12(11):899-906. PubMed ID: 15340362
[TBL] [Abstract][Full Text] [Related]
9. Score tests for familial correlation in genotyped-proband designs.
Carroll RJ; Gail MH; Benichou J; Pee D
Genet Epidemiol; 2000 Apr; 18(4):293-306. PubMed ID: 10797590
[TBL] [Abstract][Full Text] [Related]
10. Segregation analysis of 231 Ashkenazi Jewish families for evidence of additional breast cancer susceptibility genes.
Kaufman DJ; Beaty TH; Struewing JP
Cancer Epidemiol Biomarkers Prev; 2003 Oct; 12(10):1045-52. PubMed ID: 14578141
[TBL] [Abstract][Full Text] [Related]
11. CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers.
Kadouri L; Easton DF; Edwards S; Hubert A; Kote-Jarai Z; Glaser B; Durocher F; Abeliovich D; Peretz T; Eeles RA
Br J Cancer; 2001 Jul; 85(1):36-40. PubMed ID: 11437399
[TBL] [Abstract][Full Text] [Related]
12. Estimating risk of breast cancer in carriers of BRCA1 and BRCA2 mutations: a meta-analytic approach.
Fu R; Harris EL; Helfand M; Nelson HD
Stat Med; 2007 Apr; 26(8):1775-87. PubMed ID: 17243094
[TBL] [Abstract][Full Text] [Related]
13. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
14. Optimal designs for estimating penetrance of rare mutations of a disease-susceptibility gene.
Gong G; Whittemore AS
Genet Epidemiol; 2003 Apr; 24(3):173-80. PubMed ID: 12652521
[TBL] [Abstract][Full Text] [Related]
15. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
Milne RL; Osorio A; Cajal TR; Vega A; Llort G; de la Hoya M; Díez O; Alonso MC; Lazaro C; Blanco I; Sánchez-de-Abajo A; Caldés T; Blanco A; Graña B; Durán M; Velasco E; Chirivella I; Cardeñosa EE; Tejada MI; Beristain E; Miramar MD; Calvo MT; Martínez E; Guillén C; Salazar R; San Román C; Antoniou AC; Urioste M; Benítez J
Clin Cancer Res; 2008 May; 14(9):2861-9. PubMed ID: 18451254
[TBL] [Abstract][Full Text] [Related]
16. Adjustment for competing risk in kin-cohort estimation.
Chatterjee N; Hartge P; Wacholder S
Genet Epidemiol; 2003 Dec; 25(4):303-13. PubMed ID: 14639700
[TBL] [Abstract][Full Text] [Related]
17. Penetrance of BRCA1/BRCA2 specific gene mutations in Iranian women with breast cancer.
Hashemian AH; Hajizadeh E; Kazemnejad A; Atri M; Mehdipour P
Saudi Med J; 2009 Jan; 30(1):41-4. PubMed ID: 19139771
[TBL] [Abstract][Full Text] [Related]
18. Case-control and case-only designs with genotype and family history data: estimating relative risk, residual familial aggregation, and cumulative risk.
Chatterjee N; Kalaylioglu Z; Shih JH; Gail MH
Biometrics; 2006 Mar; 62(1):36-48. PubMed ID: 16542227
[TBL] [Abstract][Full Text] [Related]
19. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.
King MC; Marks JH; Mandell JB;
Science; 2003 Oct; 302(5645):643-6. PubMed ID: 14576434
[TBL] [Abstract][Full Text] [Related]
20. High risk of contralateral breast carcinoma in women with hereditary/familial non-BRCA1/BRCA2 breast carcinoma.
Shahedi K; Emanuelsson M; Wiklund F; Gronberg H
Cancer; 2006 Mar; 106(6):1237-42. PubMed ID: 16475207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
